Last Updated: Wednesday, January 16, 2013
Principal Investigator: Jeremy M. Veenstra-VanderWeele, M.D.
Other researchers: Cassandra Newsom, PhD and Kevin Sanders, MD
Research has identified the protein MGLUR5 as a neurochemical target for reducing characteristic behavior problems in adults with Fragile X. This medication should block this protein from being used in the brain.
The purpose of this study is to assess the safety and usefulness of three doses in treating behavioral symptoms of Fragile X.
Read more about Fragile X research at Vanderbilt by clicking here.
Adults 18-45 with Fragile X syndrome
Compensation for time and travel.
Nine visits - between 1 and 3 hours in length.
Adolescents (12-17 years old) with Fragile X syndromeCompensation: Yes
Adolescents and young adults (12-25 years old) with Fragile X syndromeCompensation: Yes
Children with a confirmed diagnosis of Fragile X between 3 and 11 years.Compensation: Yes
Adults age 16– 50 with Fragile X for a study using an investigational drug.Compensation: Yes
We are looking for children ages 6-12 with Autism, Asperger’s Syndrome, or PPD-NOS.Compensation: Yes
Visit this investigator's people page to list all of their studies together.